Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction

Journal of the American College of Cardiology

Volumn 60, Issue 22, 2012, Pages 2296-2304

  Leonardi, Sergio ^a,b   Thomas, Laine ^a   Neely, Megan L ^a   Tricoci, Pierluigi ^a   Lopes, Renato D ^a   White, Harvey D ^c   Armstrong, Paul W ^d   Giugliano, Robert P ^e   Antman, Elliott M ^e   Califf, Robert M ^f   Newby, L Kristin ^a   Mahaffey, Kenneth W ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Green Lane Cardiovascular Service ^*  (New Zealand)

^d UNIVERSITY OF ALBERTA   (Canada)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angioplasty; cardiovascular; clinical trial; creatine kinase; diagnostic techniques; endpoint determination; myocardial infarction; surrogate endpoint

Indexed keywords

CREATINE KINASE MB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS;

EID: 84870243381     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.09.005     Document Type: Article

References (29)

1. M.T. Roe, K.W. Mahaffey, R. Kilaru Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes Eur Heart J 25 2004 313 321
2. J.H. Alexander, R.A. Sparapani, K.W. Mahaffey Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy JAMA 283 2000 347 353
3. K.M. Akkerhuis, J.H. Alexander, B.E. Tardiff Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 105 2002 554 556
4. K. Thygesen, J.S. Alpert, H.D. White Universal definition of myocardial infarction J Am Coll Cardiol 50 2007 2173 2195
5. S. Leonardi, L.K. Newby, E.M. Ohman, P.W. Armstrong Lack of implementation of ESC/ACC definition of myocardial infarction in contemporary randomized clinical trials Circulation 122 2010 A11021
6. D.E. Cutlip, R.E. Kuntz Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes Circulation 112 2005 916 922
7. D.R. Holmes Jr, P.B. Berger Troponisms, necrosettes, enzyme leaks, creatinine phosphokinase bumps, and infarctlets: what's behind this new lexicon and what does it add? Circulation 104 2001 627 629
8. J. Herrmann Peri-procedural myocardial injury: 2005 update Eur Heart J 26 2005 2493 2519
9. S. Kaul, G.A. Diamond Trial and error How to avoid commonly encountered limitations of published clinical trials J Am Coll Cardiol 55 2010 415 427
10. A. Prasad, B.J. Gersh, M.E. Bertrand Prognostic significance of periPCI-related versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol 54 2009 477 486
11. R.P. Giugliano, J.A. White, C. Bode EARLY ACS Investigators Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
12. J.J. Ferguson, R.M. Califf, E.M. Antman SYNERGY Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
13. R.P. Giugliano, L.K. Newby, R.A. Harrington EARLY ACS Steering Committee The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome - study design and rationale Am Heart J 149 2005 994 1002
14. SYNERGY Executive Committee Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors The SYNERGY trial: study design and rationale Am Heart J 143 2002 952 960
15. C.B. Granger, R.J. Goldberg, O.H. Dabbous GRACE Investigators Predictors of hospital mortality in the Global Registry of Acute Coronary Events Arch Intern Med 163 2003 2345 2353
16. V. Montori, G. Permanyer-Miralda, I. Ferreira-Gonzalez, J. Busse, V. Pachero-Huergo, D. Bryant Validity of composite end points in clinical trials BMJ 330 2005 594 596
17. S. Kaul, G.A. Diamond Trial and error How to avoid commonly encountered limitations of published clinical trials J Am Coll Cardiol 55 2010 415 427
18. I. Ferreira-Gonzalez, G. Permanyer-Miralda, J.W. Busse Methodologic discussions for using and interpreting composite end points are limited, but still identify major concerns J Clin Epidemiol 60 2007 651 657
19. I. Ferreira-Gonzalez, J.W. Busse, D. Heels-Ansdell Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials BMJ 334 2007 786
20. P.W. Armstrong, C.M. Westerhout, F. Van de Werf Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial Am Heart J 161 2011 848 854
21. D.P. Chew, D.L. Bhatt, A.M. Lincoff, K. Wolski, E.J. Topol Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk Heart 92 2006 945 950
22. R.J. de Winter, F. Windhausen, J.H. Cornel Early invasive versus selectively invasive management for acute coronary syndromes N Engl J Med 353 2005 1095 1104
23. P. Damman, A. Hirsch, F. Windhausen, J.G. Tijssen, R.J. de Winter ICTUS Investigators 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome J Am Coll Cardiol 55 2010 858 864
24. P. Damman, L. Wallentin, K.A. Fox Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR) Circulation 125 2012 568 576
25. M.P. Bonaca, S.D. Wiviott, E. Braunwald American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) Circulation 125 2012 577 583
26. N. Freemantle, M. Calvert, J. Wood, J. Eastaugh, C. Griffin Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 289 2003 2554 2559
27. N.L. Mills, A.M. Churchhouse, K.K. Lee Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome JAMA 305 2011 1210 1216
28. M.Y. Chan, R.C. Becker, R.A. Harrington Noninvasive, medical management for non-ST-elevation acute coronary syndromes Am Heart J 155 2008 397 407
29. M.Y. Chan, K.W. Mahaffey, L.J. Sun Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease J Am Coll Cardiol Intv 1 2008 369 378